This is wonderful news, indeed- i hope there are more fantastic results and advances in this area !
The version of the drug that's already on the market costs about $1,800 for 60g. However, Medicare's partial coverage does apply to many drugs that may be prescribed to Alzheimer's patients—and this one doesn't fall under the categories of the ones it doesn't cover (barbiturates and benzodiazepines).
For those who haven't noticed yet, these scientists were testing with a surely modified version of something that already exists: Bexarotene.
The wiki page for it is pretty accurate with its cautioning. Fixing a strain of mice genetically engineered to get Alzheimer's does not necessarily mean it will work in humans, though it is always okay to be hopeful.
If the Alzheimer-model mice get it for the same reasons humans get it, maybe it will. If the mechanism it acts by is independent of the mechanism of plaque production (probably the ideal case for the pharma industry), then it maybe it will.
If we're fixing some deficiency or problem in the mice that causes their plaques but is unrelated to the human form of the disorder, then it probably won't help. If we are just stopping plaque formation (some people think the plaques are actually a protective mechanism used by your body to prevent misfolded proteins from gumming other things up), then it probably won't help.
This is good news...
Spoiler: show
Brains work the same.
But human and murine biochemistry do not, as evidenced by the startling lack of cancer cures.